Sparteine

Known as: Sparteine [Chemical/Ingredient], 7,14-Methano-2H,6H-dipyrido(1,2-a:1',2'-e)(1,5)diazocine, dodecahydro-, (7S-(7alpha,7aalpha,14alpha,14abeta))-, Sparteine, (7S-(7alpha,7aalpha,14alpha,14abeta))-Isomer 
A quinolizidine alkaloid isolated from several FABACEAE including LUPINUS; SPARTIUM; and CYTISUS. It has been used as an oxytocic and an anti… (More)
National Institutes of Health

Related topics

Related topics

27 relations

Narrower (15)

10,17-dioxosparteine13-hydroxylupanine17-oxosparteine2-dehydrosparteine
(More)

Broader (3)

AlkaloidsAnti-Arrhythmia AgentsOxytocics
In BloodProcess of secretionagonistsanalogs & derivatives
(More)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1996
Highly Cited
1996
Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects
Objective: Codeine O-demethylation to morphine is catalysed by the genetic polymorphic sparteine oxygenase (CYP2D6). The… (More)
  • table 1
  • figure 1
  • figure 3
  • figure 2
  • table 2
Is this relevant?
Highly Cited
1994
Highly Cited
1994
The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes.
The impact of gender, use of oral contraceptive steroids (OCS), coffee consumption and of smoking on the metabolism of sparteine… (More)
Is this relevant?
Highly Cited
1991
Highly Cited
1991
Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
Four different mutations of the cytochrome P450 CYP2D6 gene associated with the poor metabolizer phenotype (PM) of the… (More)
Is this relevant?
Highly Cited
1991
Highly Cited
1991
Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.
The debrisoquine/sparteine polymorphism is associated with a clinically important genetic deficiency of oxidative drug metabolism… (More)
Is this relevant?
Review
1990
Review
1990
The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects.
It has been established that the metabolism of more than twenty drugs, including antiarrhythmics, beta-adrenoceptor antagonists… (More)
Is this relevant?
Highly Cited
1990
Highly Cited
1990
Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine.
The analgesic efficacy and kinetics of a single oral dose of 75 mg codeine was investigated in 12 extensive metabolizers and 12… (More)
Is this relevant?
Review
1990
Review
1990
The genetic polymorphism of debrisoquine/sparteine metabolism-molecular mechanisms.
The genetic polymorphism of debrisoquine/sparteine metabolism is one of the best studied examples of a genetic variability in… (More)
Is this relevant?
1985
1985
Sparteine oxidation polymorphism in Denmark.
Sparteine oxidation was polymorphic among 301 healthy Danish volunteers. Hence 22 subjects or 7.3% were phenotyped as poor… (More)
Is this relevant?
1982
1982
Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.
Thirty-eight healthy subjects were given single oral doses of debrisoquine and sparteine in a crossover study. The close… (More)
Is this relevant?
Highly Cited
1979
Highly Cited
1979
Defective N-oxidation of sparteine in man: A new pharmacogenetic defect
Sparteine, an antiarrhythmic and oxytocic drug, is metabolised by N1-oxidation. The sparteine-N1-oxide rearranges with loss of… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?